PhaseBio Pharmaceuticals EV/FCF

EV/FCF of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/FCF growth rates and interactive chart. A valuation metric that measures the enterprise value of a stock compared to its free cash flow. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low EV/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current EV/FCF of PhaseBio Pharmaceuticals is -1.85 (as of December 31, 2021)
  • EV/FCF for the quarter ending March 31, 2022 was -0.83 (a -54.97% decrease compared to previous quarter)
  • Year-over-year quarterly EV/FCF decreased by -67.28%
  • Annual EV/FCF for 2021 was -1.85 (a 39.19% increase from previous year)
  • Annual EV/FCF for 2020 was -1.33 (a -50.36% decrease from previous year)
  • Annual EV/FCF for 2019 was -2.68 (a -235.2% decrease from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/FCF of PhaseBio Pharmaceuticals

Most recent EV/FCFof PHAS including historical data for past 10 years.

Interactive Chart of EV/FCF of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals EV/FCF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -0.83
2021 -1.85 -2.57 -2.55 -1.85
2020 -0.9 -1.33
2019 -2.68 -1.37 -10.3 -11.08 -2.68
2018 1.98 1.03 1.98

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology